The Biotech Voyager

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.

ASGCT week moved fast. Too fast.
So we’re doing a live aftershow on Monday, 11 AM to 12:30 PM EST to break down what happened at ASGCT 2026, the key insights, what surprised us, and what to watch next.

Since this is a special one-off event, we will also stream this one live on Linkedin.

We'll also have a special guest... so stay tuned.

Come hang out with us.

Add in your takeaways.

See you there!

The Biotech Voyager is going live from 28 Capital's Back Bay offices on Monday to set the stage for ASGCT.
We'll be covering the sessions, posters, and conversations worth your time this year, with guest appearances from NanoMosaic and Precede Bio sharing what they're bringing to the meeting.
If you're heading to ASGCT or following from afar, tune in for a focused primer before the chaos begins.

Huge stories shaping the future of medicine this week.

Researchers are using ultrasound to deliver gene therapy, bypassing traditional delivery methods entirely. Epigenetic editors are offering a new way to modify gene expression without cutting DNA. And a company developing gamma delta T cell engagers just closed an $83M Series A, a massive bet on a less explored branch of cancer immunotherapy.

Ben and Jeff break down the science behind each story and what it means for the future of biotech.

Tune in live Tuesdays and Thursdays at 11AM EST on The Biotech Voyager.

Diaconos Oncology just released new data in pancreatic cancer, one of the deadliest and hardest-to-treat cancers on the planet. But their approach isn't a typical drug.

Ben and Jeff break down how dendritic cell vaccines work, why conventional cancer vaccines keep falling short, and what makes this approach different. Plus, RNA exon editing technology that rewrites disease at the RNA level without touching your DNA, and how AI is quietly transforming surgical pathology.

New Episodes Monday, Tuesday and Thursday at 11am EST

In vivo CAR-T keeps stacking wins, AI quietly invades the operating room, and cancer vaccines stage their second act... plus, John Boyce from 28 Capital joins the show.

The show will break down the in vivo CAR-T streak that's reshaping how the industry thinks about cell therapy economics, dig into where AI is actually showing up in surgical workflows (and where the hype outpaces the data), and unpack why cancer vaccines are suddenly worth a second look after a decade in the wilderness.

Then John Boyce from 28 Capital joins to talk early-stage biotech investing, what's catching his attention right now, and where he thinks the smart money is rotating in 2026.

Asgard's AT-108 might be the most insane immunotherapy of 2026. .. a first-in-class in vivo cell reprogramming play for cancer.
Meanwhile, CNS gene therapy is having a moment: AviadoBio is crossing the blood-brain barrier, Avista's AI-designed capsids are heading to the eye and CSF, and Tenaya just dropped one-year cardiac gene therapy data at ASGCT.
Plus: Dr. Nicole Paulk joins live! Her work on CNS-directed AAV gene therapy for glioma puts her right at the center of where this field is heading.

Live on the Biotech Voyager.
(Both YouTube and Linkedin)